

John Horowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11521610/publications.pdf>

Version: 2024-02-01

35
papers

10,343
citations

430442

18
h-index

377514

34
g-index

35
all docs

35
docs citations

35
times ranked

10782
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
2	Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. <i>American Heart Journal</i> , 2010, 159, 331-339.	1.2	407
3	Metabolic Modulation With Perhexiline in Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 3280-3288.	1.6	322
4	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	1.2	224
5	Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. <i>International Journal of Cardiology</i> , 2014, 174, 696-701.	0.8	207
6	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
7	N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284.	1.2	191
8	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet</i> , 2012, 380, 1749-1758.	6.3	175
9	Meta-Analysis of Clinical Correlates of Acute Mortality in Takotsubo Cardiomyopathy. <i>American Journal of Cardiology</i> , 2014, 113, 1420-1428.	0.7	175
10	Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014, 168, 303-309.	1.2	128
11	Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). <i>European Heart Journal</i> , 2014, 35, 1255-1262.	1.0	121
12	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 625-634.	1.6	110
13	Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. <i>Heart</i> , 2012, 98, 1278-1284.	1.2	100
14	Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to Dilated Cardiomyopathy. <i>JACC: Heart Failure</i> , 2015, 3, 202-211.	1.9	77
15	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517.	1.2	67
16	Tako-Tsubo Cardiomyopathy: A Heart Stressed Out of Energy?. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 985-987.	2.3	57
17	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	1.5	37
18	Right Ventricular Involvement and Recovery After Acute Stress-Induced (Tako-tsubo) Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 775-780.	0.7	29

#	ARTICLE	IF	CITATIONS
19	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	2.9	20
20	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
21	Cardiac Energetic Impairment in Heart Disease and the Potential Role of Metabolic Modulators. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 720-728.	5.1	18
22	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	1.2	16
23	The N-AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N-Acetylcysteine and ramipril for the management of Takotsubo Syndrome. <i>Contemporary Clinical Trials</i> , 2020, 90, 105894.	0.8	14
24	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	1.9	14
25	Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 660-668.	1.5	13
26	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 345-352.	1.0	13
27	Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2010, 139, 107-112.	0.8	11
28	Inorganic Nitrate in Angina Study: A Randomized Double-Blind Placebo-Controlled Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	11
29	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
30	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	1.2	6
31	Platelet Reactivity Is Independent of Left Atrial Wall Deformation in Patients with Atrial Fibrillation. <i>Mediators of Inflammation</i> , 2016, 2016, 1-5.	1.4	4
32	A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS. <i>Future Cardiology</i> , 2016, 12, 617-626.	0.5	4
33	Clinical Trials Update Esc Congress 2011. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 77-84.	1.3	2
34	Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". <i>Circulation</i> , 2014, 129, e21-2.	1.6	1
35	The Authors Reply. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 635-636.	2.3	0